CEPLAS-TransPLANT participation at the SynBioReactor Summit 2026

06/02/2026 Transfer

CEPLAS contributed a plant science perspective on research translation and innovation at the SynBioReactor Summit 2026.

Plant Sciences as a Driver for Socio-Economic Impact

On 19 and 20 January 2026, CEPLAS participated in the SynBioReactor Summit in Berlin, an event presented for the second time by the German Association for Synthetic Biology (GASB) and focused on connecting the research translation landscape in synthetic biology. The summit brought together around 200 participants, about two thirds of whom were researchers. Of these, roughly half were academic researchers with a strong interest in research translation, while the other half were startup founders who had already moved from academia into entrepreneurship, motivated to apply their science toward real-world impact. The remaining participants included investors, industry experts, and ecosystem connectors, forming a diverse innovation ecosystem.

The audience’s energy and enthusiasm created an inspiring atmosphere and reinforced a shared sense of possibility and momentum across the SynBio community. In this setting, CEPLAS demonstrated its relevance as an innovation driver by developing the fundamental research needed to build the framework for translating plant science into SMART plants, helping to address global challenges such as climate change, limited natural resources, and threats to global food supplies.

CEPLAS Representation at the SynBioReactor Summit

CEPLAS was represented at the SynBioReactor Summit through TransPLANT, a science community project hosted within CEPLAS to support the transfer of excellent academic research toward socio-economic impact. CEPAS-TransPLANT brought a delegation of eight members, predominantly early-career researchers, and participated with both a booth and a main stage presentation. Through these formats, CEPLAS showcased its research profile, infrastructure, training environment, and its vision of SMART plants as next generation aims in synthetic biology.

CEPLAS’s presence enabled engagement with a wide range of stakeholders, including prospective PhD candidates and postdoctoral researchers, patent attorneys specializing in biotechnology, food, agriculture, and bio-factory innovation, as well as ecosystem enablers. Investors such as SPRIND, Corteva, and FoodLabs also played an important role at the event. The plant-centered perspective resonated particularly strongly with researchers pursuing plant-based synthetic biology ventures focused on biomanufacturing high-value molecules in plants.

For the attending CEPLAS early-career researchers, the summit provided valuable insight into translational pathways for positively impacting society. They also connected with potential future employers and identified peers with shared interests in research translation, some of whom could become sponsored research collaborators or startup co-founders. These exchanges highlighted a desire for stronger connections among CEPLAS early-career researchers interested in research translation and sparked discussions about establishing a dedicated initiative to support plant-synbio startups, projects, and collaborations within the cluster.

Emerging Pathways for Translational Plant Science

Encounters at the summit highlighted that translating plant research into socio-economic impact is a rapidly advancing field. Startups such as Bright Biotech demonstrated how plant synthetic biology is already being applied as a scalable platform for biomanufacturing, while discussions with funding bodies such as SPRIND showed a strong willingness to support bold and ambitious innovation pathways. SPRIND emphasized its focus on disruptive technologies rather than incremental progress and its readiness to provide substantial funding, with some initiatives securing up to 90 million euros.

Dominic Schirmer, Florian Hänsel and Ricardo Godinez-Moreno

Back